Walgreens Boots Alliance, Inc. (WBA)
| Market Cap | 15.18B |
| Revenue (ttm) | 144.60B |
| Net Income (ttm) | -6.04B |
| Shares Out | 862.71M |
| EPS (ttm) | -7.00 |
| PE Ratio | n/a |
| Forward PE | 6.01 |
| Dividend | $1.69 (9.60%) |
| Ex-Dividend Date | Feb 16, 2024 |
| Volume | 7,808,647 |
| Open | 17.74 |
| Previous Close | 17.81 |
| Day's Range | 17.53 - 17.89 |
| 52-Week Range | 17.51 - 35.38 |
| Beta | 0.75 |
| Analysts | Hold |
| Price Target | 26.23 (+49.03%) |
| Earnings Date | Jun 25, 2024 |
About WBA
Walgreens Boots Alliance, Inc. operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise. The International segment offers sale of p... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for WBA stock is "Hold." The 12-month stock price forecast is $26.23, which is an increase of 49.03% from the latest price.
News
Walgreens Boots Alliance Declares Quarterly Dividend
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the p...
Walgreens To Launch $24 Billion Business Dedicated To Specialty Pharmacy
Walgreens is launching Walgreens Specialty Pharmacy, a $24 billion business that integrates new gene and cell services with existing pharmacy assets including the large specialty pharmacy and home del...
Walgreens to help bring cell and gene therapies to patients as it expands specialty pharmacy services
Among the company's investments to "transform" its specialty pharmacy services is the opening of a new facility dedicated to cell and gene therapy services.
Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient ou...
DoorDash and Walgreens Launch Unprecedented Access for SNAP Customers
SAN FRANCISCO--(BUSINESS WIRE)--DoorDash (NASDAQ: DASH), the local commerce platform, and Walgreens (NASDAQ: WBA), a trusted, neighborhood health destination serving nearly 10 million customers each d...
Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday April 27
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is calling on the public to help in the fight against prescription drug abuse by taking part in National Prescription Drug Take Back Day on Saturday, April ...
Should You Pick Walgreens Stock At $20?
Walgreens recently reported its Q2'24 results (fiscal ends in August), with revenue and earnings exceeding the street expectations. The company reported revenue of $37.1 billion and adjusted earnings ...
Walgreens Wants Pharmacists Provider Role Expanded To ‘Test And Treat'
As Walgreens Boots Alliance chief executive Tim Wentworth works to engineer a financial turnaround of the iconic drugstore chain, he and his executive team are working with state and federal regulator...
Walgreens should scale back clinics to improve outlook, Jefferies analyst says
Walgreens Boots Alliance (WBA) posted its second report, revealing a quarterly revenue that beat expectations but a narrow outlook for 2024, citing difficult conditions within the retail environment. ...
Walgreens CEO: ‘we will beat Amazon'
Tim Wentworth – the chief executive of Walgreens Boots Alliance Inc (NASDAQ: WBA) says his company offers a customer experience that's “unmatched”. What sets $WBA apart from competition?
Walgreens Boots Alliance CEO Tim Wentworth goes one-on-one with Jim Cramer
Walgreens Boots Alliance CEO Tim Wentworth sits down with 'Mad Money' host Jim Cramer to discuss the company's plan to innovate, competition from Amazon and the retail shrink problem.
Walgreens aims to deliver value as consumers seek relief: CEO
Despite beating analyst expectations on both revenue and earnings in its latest second quarter results, Walgreens Boots Alliance (WBA) narrowed its Adjusted EPS guidance for fiscal year 2024, citing a...
Walgreens Taps Personalized Marketing to Reach Deal-Seeking Consumers
As economic pressures weigh on shoppers' minds, Walgreens is leveraging its targeting capabilities to keep them engaged. On a call with analysts Thursday (March 28) discussing second-quarter fiscal 20...
Walgreens CEO on Narrowed Forecast, Shoppers Cutting Back Spending
Walgreens Boots Alliance narrowed its fiscal 2024 guidance citing a challenging retail environment, including reduced consumer spending, and the chain is on track for $1 billion in cost savings. CEO T...
Walgreens' biggest healthcare bet is floundering as it shutters 160 primary-care clinics
Walgreens' bet on VillageMD continues to flounder. It's exiting 160 VillageMD primary-care clinics, up from the previously planned 60.
Walgreens (WBA) is Seeing a Weak Consumer Environment
Jefferies has a hold rating on Walgreens (WBA). Jefferies' Brian Tanquilut discusses Walgreens most recent earnings.
Walgreens (WBA) Earnings: Turn Around Long Decline?
Walgreens (WBA) 2Q adjusted EPS came in at $1.20 versus an estimated $0.82 and revenue came in at $37.05B versus an estimated $36.48B. Morningstar's Kadyn Kim and Miramar Capital LLC's Max Wasserman d...
Walgreens Reports Steep Loss Despite Revenue Beat on Nearly $6 Billion Impairment Charge
Walgreens Boots Alliance (WBA) reported fiscal second-quarter revenue that beat estimates, though it posted a steep loss as it incurred billions of dollars in impairment charges.
Cramer's Mad Dash: Walgreens
CNBC's Jim Cramer delivers his daily Mad Dash.
Walgreens tops quarterly revenue estimates, but narrows profit outlook in ‘challenging' economy
CNBC's Bertha Coombs joins 'Squawk Box' to break down the company's quarterly earnings results.
Walgreens Boots Alliance Posts Higher 2Q Sales, Narrows Earnings Guidance
The pharmacy chain posted adjusted earnings of $1.20 a share, compared with analysts' expectations of 82 cents a share.
Walgreens beats estimates in fiscal Q2
Walgreens Boots Alliance Inc is trading up in premarket on Thursday after reporting upbeat financial results for its second quarter. Walgreens' guidance for the full year Investors are cheering also b...
Walgreen's stock gains after big profit beat, while full-year outlook was lowered
Shares of Walgreens Boots Alliance Inc. WBA, +2.49% gained 0.8% in premarket trading Thursday after the drugstore chain reported fiscal second-quarter adjusted profit and sales that rose well above ex...
Walgreens narrows full-year profit forecast and takes $5.8 billion impairment
Walgreen Boots Alliance narrowed its profit forecast for fiscal 2024 by on Thursday, citing economic challenges for its retail business, and also took a $5.8 billion impairment related to its VillageM...
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours
Walgreens Boots Alliance lost nearly $6 billion in its second quarter as the company grapples with the loss in value of its investment in doctor-staffed clinic operator VillageMD.